Directory Category: Biotechnology

Vertex Presents Data Demonstrating Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

LONDON – Friday, June 9, 2023, at 17:00 CET – Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that 12 scientific abstracts on the companyís portfolio of cystic fibrosis (CF) medicines were presented at this yearís European Cystic Fibrosis Society’s (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria. Together, the data presented show the long-term benefits of treatment with CFTR modulators as well as the importance of treating the underlying cause of CF as early in life as possible. Key data presented at this yearís conference are highlighted below.

Read More